Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Broadcast Retirement Network's Jeffrey Snyder discusses the state of investment in the life sciences with scientist and ...

This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline ...

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA ...

The biotechnology company said in its statement to the ASX that the US Food and Drug Administration (FDA) had granted ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...

The U.S. excels at funding discovery and celebrating breakthroughs, then neglects the hard work of manufacturing them at ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...